These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 17640835

  • 1. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K.
    Int J Pharm; 2008 Jan 04; 346(1-2):143-50. PubMed ID: 17640835
    [Abstract] [Full Text] [Related]

  • 2. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
    Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H.
    J Control Release; 2009 Feb 20; 134(1):18-25. PubMed ID: 19010364
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H.
    J Control Release; 2009 Jul 01; 137(1):8-14. PubMed ID: 19285528
    [Abstract] [Full Text] [Related]

  • 5. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
    Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H.
    J Control Release; 2010 Mar 03; 142(2):167-73. PubMed ID: 19861140
    [Abstract] [Full Text] [Related]

  • 6. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS, Eldin NE, Ichihara M, Ishida T, Kiwada H.
    Int J Pharm; 2012 Nov 15; 438(1-2):176-83. PubMed ID: 22944302
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H, Doi Y, Abu Lila AS, Nagao A, Ishida T, Kiwada H.
    Eur J Pharm Biopharm; 2014 May 15; 87(1):142-51. PubMed ID: 24361534
    [Abstract] [Full Text] [Related]

  • 12. Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy.
    Miyajima Y, Nakamura H, Kuwata Y, Lee JD, Masunaga S, Ono K, Maruyama K.
    Bioconjug Chem; 2006 May 15; 17(5):1314-20. PubMed ID: 16984142
    [Abstract] [Full Text] [Related]

  • 13. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.
    J Pharm Pharmacol; 2005 Oct 15; 57(10):1279-87. PubMed ID: 16259756
    [Abstract] [Full Text] [Related]

  • 14. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.
    Anticancer Res; 2009 Jun 15; 29(6):2111-20. PubMed ID: 19528471
    [Abstract] [Full Text] [Related]

  • 15. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 16. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S.
    Clin Cancer Res; 2003 Dec 15; 9(17):6551-9. PubMed ID: 14695160
    [Abstract] [Full Text] [Related]

  • 17. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer.
    Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y.
    Int J Cancer; 2002 May 01; 99(1):130-7. PubMed ID: 11948504
    [Abstract] [Full Text] [Related]

  • 18. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
    Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N.
    J Control Release; 2004 Nov 05; 100(1):41-52. PubMed ID: 15491809
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
    Abu Lila AS, Okada T, Doi Y, Ichihara M, Ishida T, Kiwada H.
    Int J Pharm; 2012 Apr 15; 426(1-2):263-270. PubMed ID: 22310465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.